- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Protagonist Therapeutics Inc (PTGX)
Protagonist Therapeutics Inc stock price live, this page displays NASDAQ PTGX stock exchange data. View the PTGX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Protagonist Therapeutics Inc real time stock price chart below.
What Is the Protagonist Therapeutics Inc Stock Price Today?
The Protagonist Therapeutics Inc stock price today is 55.01.
What Is the Stock Symbol for Protagonist Therapeutics Inc?
The stock symbol for Protagonist Therapeutics Inc is ""PTGX.""
What Stock Exchange Does Protagonist Therapeutics Inc Trade On?
Protagonist Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Protagonist Therapeutics Inc a Good Stock to Buy?
Determining whether Protagonist Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PTGX quote. (ISIN: US74366E1029)
What Is the Protagonist Therapeutics Inc Stock Price Today?
The Protagonist Therapeutics Inc stock price today is 55.01.
What Is the Stock Symbol for Protagonist Therapeutics Inc?
The stock symbol for Protagonist Therapeutics Inc is ""PTGX.""
What Stock Exchange Does Protagonist Therapeutics Inc Trade On?
Protagonist Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Protagonist Therapeutics Inc a Good Stock to Buy?
Determining whether Protagonist Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PTGX quote. (ISIN: US74366E1029)
NASDAQ
Currency in USD
55.01
-1.25(-2.22%)
Closed·
After Hours
55.010.00(0.00%)
·
Fair Value
An estimate of a Protagonist Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
54.53
57.15
52 wk Range
32.50
60.60
PTGX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
PTGX is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a Protagonist Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
54.5357.15
52 wk Range
32.5060.60
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PTGX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Protagonist Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
69.00
Upside
+25.43%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
4 analysts have revised their earnings downwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Sell
Moving Averages
Buy
Protagonist Therapeutics Inc Company Profile
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Protagonist Therapeutics Inc SWOT Analysis
Promising Pipeline | Protagonist's rusfertide and icotrokinra show potential in polycythemia vera and inflammatory bowel diseases, with projected peak sales in billions |
Financial Strength | $698M cash reserves provide runway through 2028, supporting aggressive development of early-stage assets despite current operating losses |
Competitive Edge | PN-881, a highly potent IL-17 antagonist, could revolutionize psoriasis treatment, potentially outperforming existing antibody-based therapies |
Market Outlook | Analysts set price targets ranging from $50 to $80, reflecting optimism about Protagonist's pipeline and market potential in multiple therapeutic areas |
Compare PTGX to Peers and Sector
Metrics to compare | PTGX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPTGXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 60.3x | −4.7x | −0.5x | |
PEG Ratio | −0.90 | −0.19 | 0.00 | |
Price/Book | 4.9x | 2.9x | 2.6x | |
Price / LTM Sales | 16.3x | 11.1x | 3.2x | |
Upside (Analyst Target) | 26.4% | 116.4% | 41.2% | |
Fair Value Upside | Unlock | 11.7% | 6.2% | Unlock |
Analyst Ratings
10 Buy
1 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 69.00
(+25.43% Upside)
Earnings
Latest Release
Apr 30, 2025
EPS / Forecast
-0.19 / -0.0642
Revenue / Forecast
28.30M / 39.92M
People Also Watch
FAQ
What Stock Exchange Does Protagonist Therapeutics Trade On?
Protagonist Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Protagonist Therapeutics?
The stock symbol for Protagonist Therapeutics is "PTGX."
What Is the Protagonist Therapeutics Market Cap?
As of today, Protagonist Therapeutics market cap is 3.42B.
What Is Protagonist Therapeutics's Earnings Per Share (TTM)?
The Protagonist Therapeutics EPS (TTM) is 0.91.
When Is the Next Protagonist Therapeutics Earnings Date?
Protagonist Therapeutics will release its next earnings report on 30 Jul 2025.
From a Technical Analysis Perspective, Is PTGX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Protagonist Therapeutics Stock Split?
Protagonist Therapeutics has split 0 times.
How Many Employees Does Protagonist Therapeutics Have?
Protagonist Therapeutics has 124 employees.
What is the current trading status of Protagonist Therapeutics (PTGX)?
As of 29 Jul 2025, Protagonist Therapeutics (PTGX) is trading at a price of 55.01, with a previous close of 56.26. The stock has fluctuated within a day range of 54.53 to 57.15, while its 52-week range spans from 32.50 to 60.60.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.